BLC
ACAD icon

Brown, Lisle/Cummings’s Acadia Pharmaceuticals ACAD Stock Holding History

Brown, Lisle/Cummings’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1K Hold
500
– – ﹤0.01% 556
2025
Q4 		$13.4K Hold
500
– – ﹤0.01% 471
2025
Q3 		$10.7K Hold
500
– – ﹤0.01% 496
2025
Q2 		$10.8K Hold
500
– – ﹤0.01% 496
2025
Q1 		$8.3K Hold
500
– – ﹤0.01% 513
2024
Q4 		$9.18K Buy
500
+250
+100% +$4.04K ﹤0.01% 494
2024
Q3 		$3.85K Hold
250
– – ﹤0.01% 533
2024
Q2 		$4.06K Buy
+250
New +$4.04K ﹤0.01% 521

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Brown, Lisle/Cummings's ACAD Position: Q1 2026 in Review

Brown, Lisle/Cummings held its Acadia Pharmaceuticals (ACAD) position steady in Q1 2026 at 500 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #556.

Brown, Lisle/Cummings first reported a position in ACAD in Q2 2024 and has held it in 8 quarters since. The position peaked at $13.4K in Q4 2025. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Brown, Lisle/Cummings held 500 shares of Acadia Pharmaceuticals worth $11.1K as of Q1 2026.
  • Brown, Lisle/Cummings left its Acadia Pharmaceuticals share count unchanged in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Brown, Lisle/Cummings's portfolio in Q1 2026, its #556 holding.
  • Brown, Lisle/Cummings first reported a position in Acadia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Brown, Lisle/Cummings's Acadia Pharmaceuticals position peaked at $13.4K in Q4 2025.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Brown, Lisle/Cummings's 13F filing for Q1 2026, filed 20 Apr 2026.